Epidemiological and overall survival characteristics of central nervous system tumors in Ege University Hospital
Abstract
Aim: The aim of this study was to evaluate the epidemiological and overall survival characteristics of
5877 patients diagnosed with Central Nervous System tumors in the database of Ege University
Faculty of Medicine and compare them with the literature.
Materials and Methods: 5877 cases of CNS cancer diagnosed at Ege University Hospital between
1992 and 2017 were recorded by specially trained and certified cancer registry staff of Ege University
Cancer Control, Application and Research Center(EUCRC) analyzed using linear modeling method
and Chi-Square test and p <0.05 was considered statistically significant.
Results: According to EUCRC data, the total number of cancer cases diagnosed at Ege University
Hospital between 1992 and 2017 was 117139 and CNS tumors accounted for 5% of all cancer cases
with 5877 cases. 66.7% of the most common brain tumors were observed. CNS tumors were most
frequently observed in the 50-59 age range. Brain tumors were most commonly located in the frontal
lobe. Diffuse astrocytic and oligodendroglial tumors (63%) were the most common group among brain
tumors. Similar to all CNS tumors, a linear increase was observed in the total number of brain tumors
between 1992 and 2017. The 5-year survival rate was found to be the highest in meningeal tumors
with a rate of 86.3%. It was observed that survival rates were the lowest in the 70-year-old group and
Glioblastomas were more common in males (60.4%). The mean survival time in glioblastomas was
11.6 months for males and 13.3 months for females.
Conclusion: In general, EUCRC data and literature data is overlapping and increase in the incidence
of CNS tumors is also seen in the data of CBTRUS, GLOBOCAN and Turkey Cancer Statistics.
References
- Louis D. N., Ohgaki H., Wiestler O. D., et al. "The 2007 WHO classification of tumours of the central nervous system." Acta neuropathologica 2007;114.2.: 97-109.
- Percy C., Holten V. V., Muir C. S., et al. "International classification of diseases for oncology." 1990.
- Ostrom Q. T., Gittleman H., Farah P., et al. "CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010." Neuro-oncology 15.suppl_2. 2013: ii1-ii56. Lee C. H., Jung K. W., Yoo H., et al. "Epidemiology of primary brain and central nervous system tumors in Korea." Journal of Korean Neurosurgical Society 2010;48. 2: 145.
- Polednak A P. "Interpretation of secular increases in incidence rates for primary brain cancer in Connecticut adults, 1965–1988." Neuroepidemiology 1996;15.1: 51-6.
- Ostrom Q. T., Gittleman H., Truitt G., et al. "CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015." Neuro-oncology 20.suppl. 2018;4: iv1-iv86.
- Ferlay J., Ervik M., Lam F., et al. ‘’Global cancer observatory: Cancer today.’’ Lyon: International Agency for Research on Cancer; 2018.
- Bray F., Ferlay J, Soerjomataram I, et al. ‘’Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.’’ CA Cancer J Clin 68: 394-324, 2018
- Custer B., Longstreth W. T., Phillip, L. E., et al. "Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study." BMC cancer 6.1 (2006): 152.
- Miranda-Filho A., Piñeros M., Soerjomataram I., et al. ‘’Cancers of the brain and CNS: Global patterns and trends in incidence.’’ Neuro-oncology 19(2):270-280, 2016
- llemani C., Matsuda T., Di Carlo V., et al. ‘’CONCORD Working Group: Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.’’ Lancet 391 (10125): 1023-1075, 2018
- Lin D. D., Lin J. L., Deng X. Y., et al. "Trends in intracranial meningioma incidence in the United States, 2004‐ 2015." Cancer medicine 8.14 (2019): 6458-67.Brodbelt A. R., Barclay M. E., Greenberg D., et al. "The outcome of patients with surgically treated meningioma in England: 1999–2013. A cancer registry data analysis." British journal of neurosurgery (2019): 1-7.
- Wrensch M., Minn Y., Chew T., et al. ‘’Epidemiology of primary brain tumors: Current concepts and review of the literature.’’ Neuro-oncology 4 (4): 278-99.
- Sencan İ., Keskinkilic B. ‘’Türkiye kanser istatistikleri’’ Ankara: T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu, 2017.
Ege Üniversitesi Hastanesi merkezi sinir sistemi tümörlerinin epidemiyolojik ve genel sağ kalım özellikleri
Abstract
Amaç: Bu çalışmanın amacı, Ege Üniversitesi Tıp Fakültesi Hastanesi veri tabanında bulunan,
merkezi sinir sistemi (MSS) tümörü tanısı ile tedavi edilen 5877 adet olgunun epidemiyolojik ve genel
sağ kalım özelliklerini istatistiksel açıdan değerlendirmek ve literatür ile karşılaştırmaktır.
Gereç ve Yöntem: 1992 ile 2017 yılları arasında Ege Üniversitesi Tıp Fakültesi Hastanesinde tanı
alan 5877 adet MSS kanseri olgusu, Ege Üniversitesi Kanserle Savaş, Uygulama ve Araştırma
Merkezi’nin (EÜKAM) özel eğitimli ve sertifikalı kanser kayıt elemanları tarafından kayıt altına alınan
veriler, Ki-kare testi ve doğrusal modelleme yöntemi kullanılarak analiz edilmiş, p<0,05 değeri anlamlı
kabul edilmiştir.
Bulgular: EÜKAM verilerine göre 1992 ile 2017 yılları arasında Ege Üniversitesi Tıp Fakültesi
Hastanesinde tanı olan toplam kanser olgu sayısı 117139 olarak bulunmuş olup MSS tümörleri, 5877
adet olgu ile tüm kanser olgularının %5’ini oluşturmuştur. %66,7 oranında en sık beyin tümörleri
izlenmiştir. MSS tümörleri en sık 50-59 yaş aralığında izlenmiştir. Beyin tümörlerinin en sık frontal lob
lokalizasyonunda yerleştiği görülmüştür. Beyin tümörleri arasında diffüz astrositik ve oligodendroglial
tümörler (%63) en sık izlenen grup olmuştur. Beyin tümörlerinin toplam sayısında da tüm MSS
tümörleriyle benzer şekilde, 1992-2017 yılları arasında doğrusal bir artış izlenmiştir. Beş yıllık sağ
kalım oranı, %86,3 oranı ile meninks tümörlerinde en fazla olduğu bulunmuştur. Sağ kalım oranlarının,
70 yaş ve üzeri grupta en düşük oranda olduğu, glioblastomların, erkeklerde (%60,4) daha sık
görüldüğü izlenmiştir. Glioblastomlarda ortalama sağ kalım süresi, erkeklerde 11,6 ay, kadınlarda ise
13,3 ay olduğu bulunmuştur.
Sonuç: Genel olarak EÜKAM verileri ve literatür bilgileri örtüşmektedir ve MSS tümörlerinin insidansında
artış olduğu; CBTRUS, GLOBOCAN ve Türkiye Kanser İstatistiği verilerinde de izlenmektedir
References
- Louis D. N., Ohgaki H., Wiestler O. D., et al. "The 2007 WHO classification of tumours of the central nervous system." Acta neuropathologica 2007;114.2.: 97-109.
- Percy C., Holten V. V., Muir C. S., et al. "International classification of diseases for oncology." 1990.
- Ostrom Q. T., Gittleman H., Farah P., et al. "CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010." Neuro-oncology 15.suppl_2. 2013: ii1-ii56. Lee C. H., Jung K. W., Yoo H., et al. "Epidemiology of primary brain and central nervous system tumors in Korea." Journal of Korean Neurosurgical Society 2010;48. 2: 145.
- Polednak A P. "Interpretation of secular increases in incidence rates for primary brain cancer in Connecticut adults, 1965–1988." Neuroepidemiology 1996;15.1: 51-6.
- Ostrom Q. T., Gittleman H., Truitt G., et al. "CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015." Neuro-oncology 20.suppl. 2018;4: iv1-iv86.
- Ferlay J., Ervik M., Lam F., et al. ‘’Global cancer observatory: Cancer today.’’ Lyon: International Agency for Research on Cancer; 2018.
- Bray F., Ferlay J, Soerjomataram I, et al. ‘’Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.’’ CA Cancer J Clin 68: 394-324, 2018
- Custer B., Longstreth W. T., Phillip, L. E., et al. "Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study." BMC cancer 6.1 (2006): 152.
- Miranda-Filho A., Piñeros M., Soerjomataram I., et al. ‘’Cancers of the brain and CNS: Global patterns and trends in incidence.’’ Neuro-oncology 19(2):270-280, 2016
- llemani C., Matsuda T., Di Carlo V., et al. ‘’CONCORD Working Group: Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.’’ Lancet 391 (10125): 1023-1075, 2018
- Lin D. D., Lin J. L., Deng X. Y., et al. "Trends in intracranial meningioma incidence in the United States, 2004‐ 2015." Cancer medicine 8.14 (2019): 6458-67.Brodbelt A. R., Barclay M. E., Greenberg D., et al. "The outcome of patients with surgically treated meningioma in England: 1999–2013. A cancer registry data analysis." British journal of neurosurgery (2019): 1-7.
- Wrensch M., Minn Y., Chew T., et al. ‘’Epidemiology of primary brain tumors: Current concepts and review of the literature.’’ Neuro-oncology 4 (4): 278-99.
- Sencan İ., Keskinkilic B. ‘’Türkiye kanser istatistikleri’’ Ankara: T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu, 2017.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Supplement |
| Authors | |
| Publication Date | December 31, 2019 |
| Submission Date | February 15, 2019 |
| Published in Issue | Year 2019Volume: 58 Suppl: 2 (Oncology) |
